SARASOTA, Fla. — February 11, 2026 — Leads & Copy — INVO Fertility, Inc. (Nasdaq: IVF) has announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, and will provide intellectual property protection on the INVOcell device through 2040.
INVOcell, the world’s first FDA-cleared intravaginal culture (IVC) system, is a patented medical device for assisted reproductive care. It allows fertilization and early embryo development to take place within a woman’s body, offering a more natural and patient-centered alternative to traditional in vitro fertilization (IVF).
The original INVOcell device design incorporated both a main chamber and a microchamber. Through years of real-world clinical use and feedback from practitioners, a simplified design featuring a single main chamber without a separate microchamber was designed.
The Company subsequently submitted the modified design for patent protection which has now been granted. INVOcell was initially granted FDA clearance in 2015 and, in 2023, received additional FDA clearance for a labeling update that extended the recommended incubation period from three days to five days.
According to Steve Shum, CEO of INVO Fertility, the official issuance of the patent marks an important milestone for the company as it continues to strengthen the intellectual property foundation around the INVOcell platform. He added that INVOcell provides an additional treatment method in the fertility market, enabling fertilization and early embryo development to occur within the patient’s body rather than a traditional laboratory incubator, and that this expanded IP coverage supports the company’s growth strategy and mission to deliver high-quality fertility care through ongoing innovation.
INVO Fertility is focused on expanding access to assisted reproductive technology (ART) care to patients. The company’s principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by the INVOcell® medical device and US-based, profitable in vitro fertilization (IVF) clinics. INVO Fertility has two operational INVO Centers in the United States and one IVF clinic and also continues to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics.
INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. The company believes the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination.
Source: INVO Fertility
